With no recent news catalysts, no visible analyst support, and no financial snapshot available, there’s no clear reason to expect an immediate upside follow-through.
Technical Analysis
Trend/Momentum: MACD histogram is positive (0.0126) but contracting, suggesting fading upside momentum rather than a fresh uptrend.
RSI (6): 46.38 (neutral), implying no strong oversold bounce signal.
Moving Averages: converging, consistent with consolidation/indecision rather than a clear trend.
Key levels: Pivot 1.18 is immediate overhead resistance; supports at 1.04 (S1) and 0.954 (S2). Upside resistances at 1.319 (R1) and 1.405 (R2).
Pattern-based forward view: modest edge at best (next day ~-0.03%, next week ~-0.13%, next month ~+1.13%), not strong enough to justify an aggressive buy now.
Positive Catalysts
and reclaims the pivot (1.18).
Neutral/Negative Catalysts
keeps the near-term bias capped unless reclaimed.
Financial Performance
No financial data available (financial snapshot error), so latest quarter season and growth trends cannot be assessed from the provided data.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target trend data provided, so Wall Street bull/bear pros/cons cannot be confirmed from the dataset.
Trading Trends note: Hedge funds neutral (no significant last-quarter trend); insiders neutral (no significant last-month trend).
Congress trading: No recent congress trading data available (last 90 days).
Wall Street analysts forecast NCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NCI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast NCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NCI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
